The combined results from transcriptomic analyses, drug susceptibility screening, and spatial transcriptomics provide a comprehensive view of DVL1’s involvement in both SIC and cancer, positioning Digoxin as a promising therapeutic strategy for regulating these pathways. The gene discussed is DVL1; the disease is cancer.